These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24348476)

  • 41. Toward realization of the promise of regenerative medicine.
    Wakao H
    Horm Mol Biol Clin Investig; 2012 Jun; 10(2):249-53. PubMed ID: 25436681
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glycolipid antigen induces long-term natural killer T cell anergy in mice.
    Parekh VV; Wilson MT; Olivares-Villagómez D; Singh AK; Wu L; Wang CR; Joyce S; Van Kaer L
    J Clin Invest; 2005 Sep; 115(9):2572-83. PubMed ID: 16138194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer.
    Gebremeskel S; Lobert L; Tanner K; Walker B; Oliphant T; Clarke LE; Dellaire G; Johnston B
    Cancer Immunol Res; 2017 Dec; 5(12):1086-1097. PubMed ID: 29054890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.
    Motohashi S; Kobayashi S; Ito T; Magara KK; Mikuni O; Kamada N; Iizasa T; Nakayama T; Fujisawa T; Taniguchi M
    Int J Cancer; 2002 Nov; 102(2):159-65. PubMed ID: 12385012
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human NKT cells express granulysin and exhibit antimycobacterial activity.
    Gansert JL; Kiessler V; Engele M; Wittke F; Röllinghoff M; Krensky AM; Porcelli SA; Modlin RL; Stenger S
    J Immunol; 2003 Mar; 170(6):3154-61. PubMed ID: 12626573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of NKT cells by Ly49: analysis of primary NKT cells and generation of NKT cell line.
    Maeda M; Lohwasser S; Yamamura T; Takei F
    J Immunol; 2001 Oct; 167(8):4180-6. PubMed ID: 11591738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells.
    Marschner A; Rothenfusser S; Hornung V; Prell D; Krug A; Kerkmann M; Wellisch D; Poeck H; Greinacher A; Giese T; Endres S; Hartmann G
    Eur J Immunol; 2005 Aug; 35(8):2347-57. PubMed ID: 16025562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
    Tulley JM; Palmer JL; Gamelli RL; Faunce DE
    Shock; 2008 Feb; 29(2):269-77. PubMed ID: 17693934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
    Courtney AN; Thapa P; Singh S; Wishahy AM; Zhou D; Sastry J
    Eur J Immunol; 2011 Nov; 41(11):3312-22. PubMed ID: 21818755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
    Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
    Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
    Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
    J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells.
    Biburger M; Tiegs G
    J Immunol; 2005 Aug; 175(3):1540-50. PubMed ID: 16034092
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.
    Petersen TR; Sika-Paotonu D; Knight DA; Simkins HM; Hermans IF
    PLoS One; 2011 Mar; 6(3):e17657. PubMed ID: 21483862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Extended Family of CD1d-Restricted NKT Cells: Sifting through a Mixed Bag of TCRs, Antigens, and Functions.
    Macho-Fernandez E; Brigl M
    Front Immunol; 2015; 6():362. PubMed ID: 26284062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
    Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
    J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity.
    Nieda M; Okai M; Tazbirkova A; Lin H; Yamaura A; Ide K; Abraham R; Juji T; Macfarlane DJ; Nicol AJ
    Blood; 2004 Jan; 103(2):383-9. PubMed ID: 14512316
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
    Fujii S; Shimizu K; Kronenberg M; Steinman RM
    Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity.
    Fujii S; Goto A; Shimizu K
    Blood; 2009 Apr; 113(18):4262-72. PubMed ID: 19164596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.